United States HIV Drugs Market to Grow at a CAGR of 4.3% During 2024-2032, Aided by the Growing Demand for Effective Medications to Treat HIV

The increase in the number of HIV cases is driving the need for necessary drugs to treat the condition, which favours the United States HIV drugs market growth. Human Immunodeficiency Virus (HIV) is a condition that targets and undermines the body's immune system. It progresses through three stages: acute, chronic, and the ultimate and most severe stage known as acquired immunodeficiency syndrome (AIDS). Medications for HIV are designed to suppress the virus, reducing viral load, thereby safeguarding the immune system and preventing transmission.

According to industry reports, there were 1.09 million individuals in the country with HIV, in 2021. Further, 36,126 people were newly diagnosed with HIV in the same year. This surge necessitates a greater demand for HIV medications to address both new and existing cases. Increased availability of testing centers can aid in early detection of HIV-positive individuals, allowing for prompt initiation of prescribed treatments to prevent severe health consequences. Additionally, innovations, such as the development of multidimensional medicines to reduce pill burden and optimise dosages, are expected to enhance HIV treatment strategies.

Male dominance among HIV-positive patients can be observed in the USA, where about 76.9% of the HIV patients were male in 2021. In addition, the age group of over 55 years remained the most affected in 2021.

In May 2024, University of Pittsburgh researchers identified promising drug candidates to reverse HIV immune evasion. Their discovery, outlined in Cell Chemical Biology, targets HIV Nef, a protein that hides infected cells from the immune system. By degrading Nef, these compounds suppress HIV replication and restore immune recognition.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Breakup by Drug Type, Drug Class, Route of Administration, and Distribution Channel:

• Based on drug type, the market is divided into antiretroviral therapy (ART) and pre-exposure prophylaxis (Prep).

• The different classes of HIV drugs are nucleoside reverse transcriptase inhibitors, multi-class combination products, protease inhibitors, HIV integrase strand transfer inhibitors, non-nucleoside reverse transcriptase inhibitors, entry inhibitors— CCR5 co-receptor antagonist, fusion inhibitors, and combination, among others.

• Based on the route of administration, the market segments include oral and topical.

• By distribution channels, the market is divided into hospital pharmacies, retail pharmacies, and online pharmacies amongst others.

Key Findings of the Report:

• The surge in the number of HIV cases globally is contributing to the demand for effective drugs and treatments to address the same.

• The improving diagnostic facilities and the advancements in drug development and biotechnology are favouring the growth of the market.

• The high investment in innovation and research and development plays a crucial role in shaping the market dynamics.

• Several companies supported by government funding are investing hefty amounts in the development of drugs to cure HIV.

Key Offerings of the Report:

• The EMR report gives an overview of the United States HIV drugs market for the periods (2017-2023) and (2024-2032).

• The report also offers historical (2017-2023) and forecast (2024-2032) market information for the drug type, drug class, route of administration, and distribution channel of HIV drugs.

• The report analyses the market dynamics, covering the key demand and price indicators in the market, along with providing an assessment of the SWOT and Porter’s Five Forces models.

The major players in the United States HIV drugs market are Gilead Sciences, Inc, Janssen Global Services, LLC (Johnson & Johnson), ViiV Healthcare group of companies (GSK), and Merck Sharp & Dohme Corp (Merck & Co), among others. The comprehensive report by EMR looks into the market share, capacity, and latest developments like mergers and acquisitions, plant turnarounds, and capacity expansions of the major players.

Key Highlights of the Report

About Us:

Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which are constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.

EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over a 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.

Contact Us:

Expert Market Research
Website: www.expertmarketresearch.com
Email: sales@expertmarketresearch.com
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.